Quantum-Si incorporated operates the first next-generation protein sequencing platform for the healthcare industries.
| Revenue (TTM) | $1.60M |
| Gross Profit (TTM) | 562,000 |
| EBITDA | $-90.06M |
| Operating Margin | -7450.00% |
| Return on Equity | -49.10% |
| Return on Assets | -26.50% |
| Revenue/Share (TTM) | $0.01 |
| Book Value | $0.92 |
| Price-to-Book | 0.90 |
| Price-to-Sales (TTM) | 101.49 |
| EV/Revenue | 33.31 |
| EV/EBITDA | 0.63 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -41.80% |
| Shares Outstanding | $198.95M |
| Float | $180.11M |
| % Insiders | 10.45% |
| % Institutions | 24.85% |
Volatility is currently expanding
BRANFORD, Conn., Aug. 18, 2026 (GLOBE NEWSWIRE) -- Quantum-Si Incorporated (Nasdaq: QSI) ("Quantum-Si," "QSI" or the "Company"), a proteomics technology company redefining protein analysis through single-molecule protein sequencing, today announced that it will be participating in the H.C.
Quantum-Si incorporated (QSI) Q2 2026 Earnings Call Transcript
Quantum-Si NASDAQ: QSI said it has moved the planned launch of its Proteus protein sequencing platform to the second quarter of 2027 from the end of 2026, citing the need for an additional integrated instrument design cycle before production. The company also announced a targeted workforce reduction of about 20% as it seeks to lower cash burn and fund the revised development timeline.
Company updates anticipated commercial launch of Proteus to Q2 2027, cost-reduction actions expected to extend cash runway into Q4 2028 and highlights estimated new market opportunities for protein sequencing BRANFORD, Conn., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), a proteomics technology company redefining protein analysis through single-molecule protein sequencing, today announced financial results for the second quarter ended June 30, 2026.
BRANFORD, Conn., July 27, 2026 (GLOBE NEWSWIRE) -- Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), a proteomics technology company redefining protein analysis through single-molecule detection, today announced that it will report financial results for the second quarter 2026 on Thursday, August 13, 2026.
BRANFORD, Conn.--(BUSINESS WIRE)--Quantum-Si and Cell Signaling Technology Partner to Advance Post-Translational Modification Analysis on Proteus™.
BRANFORD, Conn.--(BUSINESS WIRE)--Quantum-Si Announces the Expansion of the Proteus™ Roadshow.
Quantum-Si incorporated (QSI) Shareholder/Analyst Call Prepared Remarks Transcript
BRANFORD, Conn.--(BUSINESS WIRE)--Quantum-Si Reports First Quarter 2026 Financial Results and Highlights Proteus™ Development Milestones.
BRANFORD, Conn.--(BUSINESS WIRE)--Quantum-Si to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on QSI and any ticker you trade — then tracks every position and per-strategy win rate.
